Browsing Category
Pharma Industry News
4535 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Septerna’s oral hypoparathyroidism strategy gets its first human pharmacokinetic validation
SEP-479’s 3-to-4-day half-life supports once-daily dosing as Septerna targets an oral alternative in hypoparathyroidism. See what comes next.
TNX-103 Phase 3 failure forces Tenax into FDA reset after nearly 90% stock plunge
TNX-103 misses Phase 3 as Tenax shares crash nearly 90%. A 26.3-meter subgroup benefit now drives the company’s FDA rescue strategy.
Glaucoma drug NCX 470 reaches another major market as Nicox’s partner strategy pays off
NCX 470 enters China review as Nicox targets glaucoma royalties across China, the U.S. and Japan. See what the filing means for growth.
Heron Therapeutics (Nasdaq: HRTX) withdraws 2026 guidance as CINVANTI patent ruling reshapes plan
Heron Therapeutics withdrew 2026 guidance and cut $13.5m of Hercules debt after a June Delaware ruling on CINVANTI, with monthly covenants now running through 2027.
Tarsus Pharmaceuticals (NASDAQ: TARS) to add Alkeus in $800m eye pipeline deal
Tarsus lines up an $800m Alkeus deal and a $125m PIPE to enter Stargardt disease, but a 2029 readout and Belite Bio's lead still gate the retina thesis.
Can Ascendis Pharma turn two weekly injections into its next rare-disease growth engine?
Ascendis Pharma’s weekly achondroplasia combination sustains 7.7cm growth as YUVIWEL uptake builds. Read what it means for the franchise.
Platelet biomarker could shape bezisterim Phase 3 strategy after mixed investor response
Bezisterim shows broad Parkinson’s improvements, but BioVie’s stock plunge and cash needs raise doubts. Read the full Phase 2 analysis.
ADMA Biologics stock has jumped 13% in a week, so why does the August 10 lawsuit deadline still matter?
ADMA Biologics is approaching an August 10 lead-plaintiff deadline in a securities class action at a moment when stronger ASCENIV sales, higher margins and improved cash generation are complicating the investment narrative.
Avacta (AIM: AVCT) share count rises 27.7% as £41.5m funding cycle splits between trials and debt
Avacta Group Plc has added approximately 102.3 million ordinary shares since the end of 2024, reducing a non-participating holder’s proportional ownership by about 21.7% while financing clinical development and lowering convertible-bond principal.
Oxford Biomedica (LSE: OXB) plunges 15% as 2026 revenue guidance falls
Oxford Biomedica cut 2026 revenue guidance by £40m at midpoint. September results must show whether OXB’s setback is timing or something deeper.